Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Immunomedics
Woman and Man
Between 18 years
and 99 years
Immunomedics
Update Il y a 4 ans
Étude TROPHY U-01 : étude de phase 2 randomisée évaluant l’efficacité du sacituzumab govitecan chez des patients ayant un carcinome des voies excrétrices (calices, bassinet, uretères, vessie, urèthre) métastatique après échec d'un protocole à base de platine ou d'une immunothérapie anti‐PD1/PD‐L1.
Le carcinome urothélial est le type le plus fréquent de cancer de la vessie, il représente plus de 90% de tous les cancers de la vessie. Il peut subvenir dans n’importe quelle partie de l’appareil uri...
Country
France
organs
Appareil urinaire - autres
Specialty
Thérapies Ciblées
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Immunomedics, Inc
Update Il y a 4 ans
A Phase II, Single-Arm Trial of Naked Epratuzumab, an Anti-CD22 Humanized Antibody, in Patients with Waldenström's Macroglobulinemia
The primary objective is to evaluate the efficacy of epratuzumab in WM as determined by the response rate for patients with partial or complete responses.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Immunomedics, Inc
Update Il y a 4 ans
A Phase I/II Study of Immunotherapy with Subcutaneous Administered Veltuzumab (hA20) in Patients with CD20+ Non-Hodgkin's Lymphoma or Chronic Lyphocytic Leukemia
To determine if a subcutaneous dosing schedule of veltuzumab can be established in NHL or CLL paitent and to confirm safety and efficacy of veltuzumab that was previously established when administered...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Immunomedics, Inc
Update Il y a 4 ans
A Phase Ib/II Study of Fractionated 90-Y-hPAM4 Plus Gemcitabine in Patients with Previously Untreated Advanced Pancreatic Cancer
To evaluate the feasibility, safety and tolerability of this treatment regimen, and to determine acceptable 90-Y dose and gemcitabine dosing for use with this approach.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Immunomedics, Inc
Update Il y a 4 ans
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studyof Epratuzumab in Patients with Active Systemic Lupus Erythematosus
The primary study objective is to demonstrate that epratuzumab is effective for improvement of the signs and symptoms of SLE.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Immunomedics, Inc
Update Il y a 4 ans
Estudio en fase III, multicéntrico, doble-ciego, aleatorizado, controlado con placebo de Epratuzumab en pacientes con crisis agudas severas de Lupus Eritematoso Sistémico excluyendo los sistemas renal o neurológico
El objetivo principal del estudio es demostrar que epratuzumab es eficaz para el tratamiento de la exacerbación aguda de lupus.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years and 85 years
Immunomedics
Update Il y a 5 ans
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy
Country
France
organs
Appareil urinaire - autres
Specialty
Thérapies Ciblées
Essai ouvert aux inclusions
More information
Woman
Between 18 years
and 99 years
Immunomedics
Update Il y a 4 ans
Étude ASCENT : étude de phase 3 randomisée comparant l’efficacité du sacituzumab govitécan avec celle de l’éribuline, de la capécitabine, de la gemcitabine et de la vinorelbine chez des patients ayant un cancer du sein triple négatif métastatique.
Le cancer du sein est le cancer le plus fréquent chez la femme. Il représente plus du tiers de l'ensemble des nouveaux cas de cancer chez la femme. Un cancer du sein résulte d'un dérèglement de certai...
Country
France
organs
Sein
Specialty
Immunothérapie - Vaccinothérapie
,
Chimiothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Immunomedics, Inc
Update Il y a 4 ans
Radioimmunotherapy with 90Y-Clivatizumab Tetraxetan plus Low Dose Gemcitabine versus Placebo plus Low-Dose Gemcitabine
Overall Survival (OS)
Country
None
organs
None
Specialty
None
Closed trial
More information